Literature DB >> 25098969

What happens when people discontinue taking medications? Lessons from COMBINE.

Robert L Stout1, Jordan M Braciszewski, Meenakshi Sabina Subbaraman, Henry R Kranzler, Stephanie S O'Malley, Daniel Falk.   

Abstract

AIMS: We use intensive longitudinal data methods to illuminate processes affecting patients' drinking in relation to the discontinuation of medications within an alcohol treatment study. Although previous work has focused on broad measures of medication adherence, we focus on dynamic changes in drinking both before and after patients discontinue.
DESIGN: We conducted secondary data analyses using the COMBINE (Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence) study, focused on participants who discontinued medications prior to the planned end of treatment. Using an interrupted time-series analysis, we analysed drinking in the weeks before and after discontinuation and also studied outcomes at the end of the COMBINE follow-up.
SETTING: Unites States of America. PARTICIPANTS: We describe the subsample of COMBINE participants who discontinued medications (n = 450), and compare them with those who were medication-adherent (n = 559) and with those who discontinued but had substantial missing data (n = 217). MEASUREMENTS: The primary outcomes were percentage of days abstinent (PDA) and percentage of heavy drinking days (PHDD). Medication adherence data were used to approximate the date of discontinuation.
FINDINGS: For many patients, an increase in drinking began weeks before discontinuation (PDA: F(1,4803) = 19.07, P < 0.001; PHDD: F(1,4804) = 8.58, P = 0.003) then escalated at discontinuation (PDA: F(1,446) = 5.05, P = 0.025; PHDD: F(1,446) = 4.52, P = 0.034). Among other effects, the amount of change was moderated by the reason for discontinuation (e.g. adverse event; PDA: F(2,4803) = 3.85, P = 0.021; PHDD: F(2,4804) = 5.36, P = 0.005) and also whether it occurred in the first or second half of treatment (PDA: F(1,4803) = 5.23, P = 0.022; PHDD: F(1,4804) = 8.79, P = 0.003).
CONCLUSIONS: A patient's decision to stop taking medications during alcohol treatment appears to take place during a weeks-long process of disengagement from treatment. Patients who discontinue medications early in treatment or without medical consultation appear to drink more frequently and more heavily.
© 2014 Society for the Study of Addiction.

Entities:  

Keywords:  Alcohol treatment outcome; clinical intervention; imputation; medication compliance; medication study; missing data; research methods; statistics

Mesh:

Substances:

Year:  2014        PMID: 25098969      PMCID: PMC4254710          DOI: 10.1111/add.12700

Source DB:  PubMed          Journal:  Addiction        ISSN: 0965-2140            Impact factor:   6.526


  18 in total

1.  Missing data in alcohol clinical trials: a comparison of methods.

Authors:  Kevin A Hallgren; Katie Witkiewitz
Journal:  Alcohol Clin Exp Res       Date:  2013-07-24       Impact factor: 3.455

Review 2.  Elevated rates of early discontinuation from pharmacotherapy trials in alcoholics and drug abusers.

Authors:  H R Kranzler; R Escobar; D K Lee; E Meza
Journal:  Alcohol Clin Exp Res       Date:  1996-02       Impact factor: 3.455

3.  Improving naltrexone response: an intervention for medical practitioners to enhance medication compliance in alcohol dependent patients.

Authors:  H M Pettinati; J R Volpicelli; J D Pierce; C P O'Brien
Journal:  J Addict Dis       Date:  2000

Review 4.  Adherence to pharmacotherapy in patients with alcohol and opioid dependence.

Authors:  Roger D Weiss
Journal:  Addiction       Date:  2004-11       Impact factor: 6.526

5.  Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.

Authors:  Raymond F Anton; Stephanie S O'Malley; Domenic A Ciraulo; Ron A Cisler; David Couper; Dennis M Donovan; David R Gastfriend; James D Hosking; Bankole A Johnson; Joseph S LoCastro; Richard Longabaugh; Barbara J Mason; Margaret E Mattson; William R Miller; Helen M Pettinati; Carrie L Randall; Robert Swift; Roger D Weiss; Lauren D Williams; Allen Zweben
Journal:  JAMA       Date:  2006-05-03       Impact factor: 56.272

6.  Ritanserin in the treatment of alcohol dependence--a multi-center clinical trial. Ritanserin Study Group.

Authors:  B A Johnson; D R Jasinski; G P Galloway; H Kranzler; R Weinreib; R F Anton; B J Mason; M J Bohn; H M Pettinati; R Rawson; C Clyde
Journal:  Psychopharmacology (Berl)       Date:  1996-11       Impact factor: 4.530

7.  A multi-site study of alcohol subtypes: classification and overlap of unidimensional and multi-dimensional typologies.

Authors:  Elizabeth E Epstein; Erich Labouvie; Barbara S McCrady; Noelle K Jensen; Jumi Hayaki
Journal:  Addiction       Date:  2002-08       Impact factor: 6.526

8.  Testing combined pharmacotherapies and behavioral interventions for alcohol dependence (the COMBINE study): a pilot feasibility study.

Authors: 
Journal:  Alcohol Clin Exp Res       Date:  2003-07       Impact factor: 3.455

9.  Testing combined pharmacotherapies and behavioral interventions in alcohol dependence: rationale and methods.

Authors: 
Journal:  Alcohol Clin Exp Res       Date:  2003-07       Impact factor: 3.455

10.  A placebo-controlled randomized clinical trial of naltrexone in the context of different levels of psychosocial intervention.

Authors:  David W Oslin; Kevin G Lynch; Helen M Pettinati; Kyle M Kampman; Peter Gariti; Lois Gelfand; Thomas Ten Have; Shoshana Wortman; William Dundon; Charles Dackis; Joseph R Volpicelli; Charles P O'Brien
Journal:  Alcohol Clin Exp Res       Date:  2008-07       Impact factor: 3.455

View more
  3 in total

Review 1.  Guidelines for the Reporting of Treatment Trials for Alcohol Use Disorders.

Authors:  Katie Witkiewitz; John W Finney; Alex H S Harris; Daniel R Kivlahan; Henry R Kranzler
Journal:  Alcohol Clin Exp Res       Date:  2015-08-11       Impact factor: 3.455

Review 2.  Recommendations for the Design and Analysis of Treatment Trials for Alcohol Use Disorders.

Authors:  Katie Witkiewitz; John W Finney; Alex H S Harris; Daniel R Kivlahan; Henry R Kranzler
Journal:  Alcohol Clin Exp Res       Date:  2015-08-06       Impact factor: 3.455

Review 3.  Monitoring and Improving Naltrexone Adherence in Patients with Substance Use Disorder.

Authors:  Virginia Perez-Macia; Mireia Martinez-Cortes; Jesus Mesones; Manuel Segura-Trepichio; Lorena Garcia-Fernandez
Journal:  Patient Prefer Adherence       Date:  2021-05-18       Impact factor: 2.711

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.